Your browser doesn't support javascript.
loading
In vivo release of levonorgestrel from Sino-implant (II) ­ an innovative comparison of explant data.
Callahan, Rebecca L; Taylor, Douglas; Jenkins, David W; Owen, Derek H; Cheng, Linan; Cancel, Aida M; Dorflinger, Laneta J; Steiner, Markus J.
Afiliação
  • Callahan RL; FHI 360, Durham, NC 27701, USA. Electronic address: rcallahan@fhi360.org.
  • Taylor D; FHI 360, Durham, NC 27701, USA.
  • Jenkins DW; FHI 360, Durham, NC 27701, USA.
  • Owen DH; FHI 360, Durham, NC 27701, USA.
  • Cheng L; Shanghai Institute of Planned Parenthood Research (SIPPR), Shanghai, China.
  • Cancel AM; FHI 360, Durham, NC 27701, USA.
  • Dorflinger LJ; FHI 360, Durham, NC 27701, USA.
  • Steiner MJ; FHI 360, Durham, NC 27701, USA.
Contraception ; 92(4): 350-5, 2015 Oct.
Article em En | MEDLINE | ID: mdl-26142619
ABSTRACT

OBJECTIVES:

Measuring the amount of progestin remaining in contraceptive implants used for different lengths of time provides useful information on in vivo release kinetics including change over time. We compared estimated in vivo levonorgestrel (LNG) release rates derived from Sino-implant (II) explants with similar data from removed Jadelle. STUDY

DESIGN:

We measured LNG remaining in 44 sets of Sino-implant (II) used for up to 7 years and removed in four Chinese clinics. Results were compared with published data for Jadelle explants used for up to 36 months. We estimated and compared monthly and daily LNG release rates for the two products using prediction models for drug release. We also estimated the dissolution profile similarity factor, f2, for LNG release.

RESULTS:

Both Sino-implant (II) and Jadelle release approximately 30% of total LNG load after 3 years. Results of fitting the data to a biologically plausible modified Higuchi prediction model indicate comparable release through 3 years. An estimated similarity factor of 80.6 (90% confidence interval 70.8-85.7) indicates similarity in the dissolution profiles of the two implants.

CONCLUSIONS:

LNG release in vivo measured through explant analysis suggest that Sino-implant (II) and Jadelle may perform similarly through 3 years of use and could remain highly effective beyond this time point. These results align with published data for Jadelle and Sino-implant (II) showing high effectiveness for 5 years. Ongoing clinical studies comparing the products over 5 years present an opportunity to verify this supportive measure of clinical effectiveness. IMPLICATIONS This innovative approach provides evidence that Sino-implant (II) may perform clinically similarly to Jadelle over 3 years and remain a highly effective contraceptive beyond this time point. Data from explant analyses show promise for investigating the equivalence of elusion profiles of contraceptive implants.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Levanogestrel / Anticoncepcionais Femininos Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Levanogestrel / Anticoncepcionais Femininos Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article